KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Invested Capital (2016 - 2025)

Historic Invested Capital for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $6.1 billion.

  • Biomarin Pharmaceutical's Invested Capital rose 1188.38% to $6.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 billion, marking a year-over-year increase of 1188.38%. This contributed to the annual value of $5.7 billion for FY2024, which is 390.35% up from last year.
  • Biomarin Pharmaceutical's Invested Capital amounted to $6.1 billion in Q3 2025, which was up 1188.38% from $6.0 billion recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Invested Capital registered a high of $6.1 billion during Q3 2025, and its lowest value of $4.2 billion during Q1 2021.
  • Moreover, its 5-year median value for Invested Capital was $4.8 billion (2023), whereas its average is $5.0 billion.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Invested Capital crashed by 257.07% in 2021, and later surged by 2087.28% in 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Invested Capital (Quarter) stood at $4.3 billion in 2021, then rose by 7.07% to $4.6 billion in 2022, then increased by 17.89% to $5.4 billion in 2023, then rose by 3.9% to $5.7 billion in 2024, then rose by 7.05% to $6.1 billion in 2025.
  • Its Invested Capital was $6.1 billion in Q3 2025, compared to $6.0 billion in Q2 2025 and $5.8 billion in Q1 2025.